Evidence-Based Medicine Guidelines
Subcutaneous sumatriptan in migraine
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Subcutaneous Sumatriptan in Migraine." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454996/all/Subcutaneous_sumatriptan_in_migraine.
Subcutaneous sumatriptan in migraine. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/454996/all/Subcutaneous_sumatriptan_in_migraine. Accessed December 26, 2024.
Subcutaneous sumatriptan in migraine. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/454996/all/Subcutaneous_sumatriptan_in_migraine
Subcutaneous Sumatriptan in Migraine [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454996/all/Subcutaneous_sumatriptan_in_migraine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Subcutaneous sumatriptan in migraine
ID - 454996
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454996/all/Subcutaneous_sumatriptan_in_migraine
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
